STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC
- DOI
- 10.1080/14796694.2025.2485015
- Published
- 2025-04-18
- Container
- Future Oncology
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1080/14796694.2025.2485015,
title = {STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC},
author = {Nabil F. Saba and Kevin Harrington and Lisa Licitra and Jean-Pascal Machiels and Cixin He and Taylor Jew and Vasily Andrianov and Robert Haddad},
year = {2025},
journal = {Future Oncology},
doi = {10.1080/14796694.2025.2485015},
url = {https://doi.org/10.1080/14796694.2025.2485015}
}RIS
TY - JOUR TI - STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC AU - Nabil F. Saba AU - Kevin Harrington AU - Lisa Licitra AU - Jean-Pascal Machiels AU - Cixin He AU - Taylor Jew AU - Vasily Andrianov AU - Robert Haddad PY - 2025 JO - Future Oncology DO - 10.1080/14796694.2025.2485015 UR - https://doi.org/10.1080/14796694.2025.2485015 ER -
APA
Saba, N. F., Harrington, K., Licitra, L., Machiels, J., He, C., Jew, T., Andrianov, V., & Haddad, R. (2025). STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC. Future Oncology. https://doi.org/10.1080/14796694.2025.2485015
Source records
- crossref · retrieved 2026-09-25T23:57:58.645Z